文献速递基础与转化研究新药、器械与细胞基因治疗研发

吉瑞替芬逆转乳腺癌中由雌激素受体突变驱动的孕激素超敏反应

Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer.
PubMed 文献 · Sci Transl Med · 2022-09-21

研究利用Esr1突变乳腺模型和人源异种移植瘤(PDX)探索ESR1突变生物学特性及对吉瑞替芬的敏感性。Esr1突变促进孕激素超敏反应、类妊娠组织重塑和增殖,由ERα-PR在促增殖基因启动子共结合驱动。吉瑞替芬对突变ERα-PR增殖程序的抑制强于他莫昔芬和氟维司群,并对孕激素刺激的ESR1突变PDX生长有效。

要点

  • Esr1突变在乳腺中促进孕激素超敏反应、类妊娠组织重塑和显著增殖。
  • 突变ERα与PR在促增殖基因启动子区共结合,驱动增殖程序。
  • 吉瑞替芬对突变ERα-PR增殖的抑制强于他莫昔芬和氟维司群。

核心结论

  • 突变ERα可与PR协同驱动促肿瘤增殖,但仍对吉瑞替芬抑制敏感。

研究设计与样本

  • 研究构建表达Esr1突变的乳腺模型,并利用人源异种移植瘤(PDX)在体内研究ESR1突变的生物学特性及对吉瑞替芬的敏感性。
  • 另报告一例入组1期临床试验的分子特征明确的ESR1突变肿瘤患者对吉瑞替芬的活性。

主要发现

  • 在小鼠乳腺中,Esr1突变促进孕激素超敏反应,触发类妊娠组织重塑和显著升高的增殖。
  • 这些效应由改变的孕激素转录反应驱动,并以ERα-PR在促增殖基因启动子区获得共结合位点为基础。
  • PDX实验显示突变ERα-PR增殖程序在人癌细胞中同样相关。
  • 吉瑞替芬对乳腺中突变ERα-PR增殖的抑制强于标准治疗药物他莫昔芬和氟维司群。
  • 吉瑞替芬对孕激素刺激的ESR1突变PDX模型生长有效,并对一例1期临床试验患者的ESR1突变肿瘤显示活性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ESR1 (estrogen receptor 1) hotspot mutations are major contributors to therapeutic resistance in estrogen receptor-positive (ER+) breast cancer. Such mutations confer estrogen independence to ERα, providing a selective advantage in the presence of estrogen-depleting aromatase inhibitors. In addition, ESR1 mutations reduce the potency of tamoxifen and fulvestrant, therapies that bind ERα directly. These limitations, together with additional liabilities, inspired the development of the next generation of ERα-targeted therapeutics, of which giredestrant is a high-potential candidate. Here, we generated Esr1 mutant-expressing mammary gland models and leveraged patient-derived xenografts (PDXs) to investigate the biological properties of the ESR1 mutations and their sensitivity to giredestrant in vivo. In the mouse mammary gland, Esr1 mutations promote hypersensitivity to progesterone, triggering pregnancy-like tissue remodeling and profoundly elevated proliferation. These effects were driven by an altered progesterone transcriptional response and underpinned by gained sites of ERα-PR (progesterone receptor) cobinding at the promoter regions of pro-proliferation genes. PDX experiments showed that the mutant ERα-PR proliferative program is also relevant in human cancer cells. Giredestrant suppressed the mutant ERα-PR proliferation in the mammary gland more so than the standard-of-care agents, tamoxifen and fulvestrant. Giredestrant was also efficacious against the progesterone-stimulated growth of ESR1 mutant PDX models. In addition, giredestrant demonstrated activity against a molecularly characterized ESR1 mutant tumor from a patient enrolled in a phase 1 clinical trial. Together, these data suggest that mutant ERα can collaborate with PR to drive protumorigenic proliferation but remain sensitive to inhibition by giredestrant.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Liang J, Ingalla ER, Yao X, et al. Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer. Sci Transl Med. 2022. PMID: 36130016. doi:10.1126/scitranslmed.abo5959

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。